15
Participants
Start Date
November 15, 2024
Primary Completion Date
March 15, 2025
Study Completion Date
March 15, 2027
Drug：CD19 CAR-T
A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.
Institute of Hematology & Blood Diseases Hospital, China
OTHER